Sagimet Biosciences announces denifanstat met all primary, secondary endpoints

Sagimet Biosciences (SGMT) reported that data from a Phase 3 clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimet’s license partner for China, Ascletis Bioscience, will be presented at the 2025 Fall Clinical Dermatology Conference taking place October 24-26, 2025, in Las Vegas, Nevada. Key Presentation Highlights: Once daily oral 50 mg denifanstat achieved highly statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints when analyzed using an intent-to-treat analysis. At Week 12, treatment success rates with denifanstat were more than double those of placebo, with marked reductions in both inflammatory and non-inflammatory lesions. Denifanstat was generally well-tolerated.